Peptide Information

General Information of This Peptide
Peptide ID
PEP00107
Peptide Name
[Tyr3,Cys8] Octreotate amide
Structure
Sequence
NH2-FCYWKTCC
Peptide Type
Linear
Receptor Name
Somatostatin receptor type 2 (SSTR2)
  Receptor Info 
PDC Transmembrane Types Cell targeting peptides (CTPs)
Formula
C48H63N11O10S3
Isosmiles
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@@H](CS)C(N)=O)NC1=O
InChI
InChI=1S/C48H63N11O10S3/c1-26(60)40-48(69)58-39(47(68)56-37(23-70)41(51)62)25-72-71-24-38(57-42(63)32(50)19-27-9-3-2-4-10-27)46(67)54-35(20-28-14-16-30(61)17-15-28)44(65)55-36(21-29-22-52-33-12-6-5-11-31(29)33)45(66)53-34(43(64)59-40)13-7-8-18-49/h2-6,9-12,14-17,22,26,32,34-40,52,60-61,70H,7-8,13,18-21,23-25,49-50H2,1H3,(H2,51,62)(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t26-,32-,34+,35+,36-,37+,38+,39+,40+/m1/s1
InChIKey
QZHOOLOXUURHNN-AQLQTPEZSA-N
Pharmaceutical Properties
Molecule Weight
1050.3
Polar area
355.08
Complexity
1049.39215
xlogp Value
-1.0578
Heavy Count
72
Rot Bonds
17
Hbond acc
15
Hbond Donor
14
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
PEN-221 [Phase 2]
 PDC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Small cell lung cancer
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.06 µmol/L
Administration Time 6 h
Description
PEN-221 receptor dependent activity in vitro varied from strong (NCI-H524) to modest (HCC-33) but was consistent (N = 3) and correlated with in vivo activity (described below). Octreotide alone did not have an effect on cellular growth. These cell lines also demonstrated sensitivity to the cytotoxic payload, DM1, with sub-micromolar IC50's after a 6-hour exposure and 70-hour additional incubation period (Supplementary Fig. S2B).

   Click to Show/Hide
In Vitro Model Lung small cell carcinoma NCI-H524 cell CVCL_1568
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Small cell lung cancer
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.108 µmol/L
Administration Time 6 h
Description
PEN-221 receptor dependent activity in vitro varied from strong (NCI-H524) to modest (HCC-33) but was consistent (N = 3) and correlated with in vivo activity (described below). Octreotide alone did not have an effect on cellular growth. These cell lines also demonstrated sensitivity to the cytotoxic payload, DM1, with sub-micromolar IC50's after a 6-hour exposure and 70-hour additional incubation period (Supplementary Fig. S2B).

   Click to Show/Hide
In Vitro Model Small cell lung carcinoma NCI-H69 cell CVCL_1579
Experiment 3 Reporting the Activity Data of This PDC [1]
Indication Small cell lung cancer
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.258 µmol/L
Administration Time 6 h
Description
PEN-221 receptor dependent activity in vitro varied from strong (NCI-H524) to modest (HCC-33) but was consistent (N = 3) and correlated with in vivo activity (described below). Octreotide alone did not have an effect on cellular growth. These cell lines also demonstrated sensitivity to the cytotoxic payload, DM1, with sub-micromolar IC50's after a 6-hour exposure and 70-hour additional incubation period (Supplementary Fig. S2B).

   Click to Show/Hide
In Vitro Model Small cell lung carcinoma NCI-H69 cell CVCL_1579
Experiment 4 Reporting the Activity Data of This PDC [1]
Indication Small cell lung cancer
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.333 µmol/L
Administration Time 6 h
Description
PEN-221 receptor dependent activity in vitro varied from strong (NCI-H524) to modest (HCC-33) but was consistent (N = 3) and correlated with in vivo activity (described below). Octreotide alone did not have an effect on cellular growth. These cell lines also demonstrated sensitivity to the cytotoxic payload, DM1, with sub-micromolar IC50's after a 6-hour exposure and 70-hour additional incubation period (Supplementary Fig. S2B).

   Click to Show/Hide
In Vitro Model Lung small cell carcinoma NCI-H524 cell CVCL_1568
Experiment 5 Reporting the Activity Data of This PDC [1]
Indication Small cell lung cancer
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.658 µmol/L
Administration Time 6 h
Description
PEN-221 receptor dependent activity in vitro varied from strong (NCI-H524) to modest (HCC-33) but was consistent (N = 3) and correlated with in vivo activity (described below). Octreotide alone did not have an effect on cellular growth. These cell lines also demonstrated sensitivity to the cytotoxic payload, DM1, with sub-micromolar IC50's after a 6-hour exposure and 70-hour additional incubation period (Supplementary Fig. S2B).

   Click to Show/Hide
In Vitro Model Lung small cell carcinoma HCC33 cell CVCL_2058
Experiment 6 Reporting the Activity Data of This PDC [1]
Indication Small cell lung cancer
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.83 µmol/L
Administration Time 6 h
Description
PEN-221 receptor dependent activity in vitro varied from strong (NCI-H524) to modest (HCC-33) but was consistent (N = 3) and correlated with in vivo activity (described below). Octreotide alone did not have an effect on cellular growth. These cell lines also demonstrated sensitivity to the cytotoxic payload, DM1, with sub-micromolar IC50's after a 6-hour exposure and 70-hour additional incubation period (Supplementary Fig. S2B).

   Click to Show/Hide
In Vitro Model Lung small cell carcinoma HCC33 cell CVCL_2058
References
Ref 1 Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. Mol Cancer Ther. 2019 Nov;18(11):1926-1936. doi: 10.1158/1535-7163.MCT-19-0022.